So it seems Novartis initially targeted a large group of NYHA 2-4 patients for the trial. (very specific inclusion criteria, read the paper of you're interested)
On analysis of that group they didn't quite meet significance.
When they analysed subgroups (prespecified prior to analysis, not post) they found significant benefit in women and patients with a lower ejection fraction.
The benefit to having a large N is that if you break down into subgroups you can still get significance.
With an N of 560 or whatever, you break it down and may only have subgroups of 100, so you need a much stronger improvement to get significance.
Hopefully MSB can do this.
I recommend everyone calling out corruption go and read for themselves. All the data is available.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)